These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28767562)

  • 1. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
    Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
    Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
    Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
    Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
    J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
    Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
    J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
    Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
    J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of various RAS codon mutations and prognostic outcomes of patients with colorectal liver metastases after hepatectomy.
    Wu XG; Liu W; Wang YY; Wang K; Xing BC
    Cancer Med; 2024 Oct; 13(19):e70168. PubMed ID: 39377605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.
    Zimmitti G; Shindoh J; Mise Y; Kopetz S; Loyer EM; Andreou A; Cooper AB; Kaur H; Aloia TA; Maru DM; Vauthey JN
    Ann Surg Oncol; 2015 Mar; 22(3):834-842. PubMed ID: 25227306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.
    Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN
    Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery.
    Chun YS; Passot G; Nishioka Y; Katkhuda R; Arvide EM; Benzerdjeb N; Lopez J; Kopetz SE; Maru DM; Vauthey JN
    J Am Coll Surg; 2022 Jul; 235(1):8-16. PubMed ID: 35703957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
    Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
    Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
    Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
    Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
    Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
    Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
    Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
    Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
    Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
    Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.